• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Persistent Drug Shortages in the United States: Analyses & Strategies

Persistent Drug Shortages in the United States: Analyses & Strategies

9781633211742
875,64 zł
788,07 zł Zniżka 87,57 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 788,07 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
From prolonged duration of a disease, to permanent injury, to death, drug shortages have led to harmful outcomes for patients of all ages. Over the last decade, an increasing number of prescription drugs -- including life-saving and life-sustaining drugs -- have been in short supply, preventing health care providers and patients from accessing medications that are essential for treatment. During shortages, providers -- including hospitals, physicians, and pharmacists -- may have to use medications that could be less effective for treating conditions or carry unwanted side-effects, if alternatives are available at all. The immediate cause of drug shortages can generally be traced to a manufacturer halting or slowing production to address quality problems, triggering a supply disruption. Other manufacturers have a limited ability to respond to supply disruptions due to constrained manufacturing capacity. This book reviews the trends in recent drug shortages and describes what is known about their effect on patients and providers; examines the causes of drug shortages; and evaluates the progress FDA has made in addressing drug shortages.
Szczegóły produktu
74619
9781633211742
9781633211742

Opis

Rok wydania
2014
Numer wydania
1
Oprawa
twarda
Liczba stron
160
Wymiary (mm)
180.00 x 260.00
Waga (g)
374
  • Preface; Drug Shortages:: Public Health Threat Continues, Despite Efforts to Help Ensure Product Availability; Statement of Douglas C Throckmorton, Deputy Director of Regulatory Programs, U.S. Food & Drug Administration. Hearing on Examining Drug Shortages & Recent Efforts to Address Them; Strategic Plan for Preventing & Mitigating Drug Shortages; FDAs Contribution to the Drug Shortage Crisis; Index.
Komentarze (0)